drugset / Trial / NCT07265947
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
Timeline
- Start
- 2025-12-22
- Primary completion
- 2030-10
- Completion
- 2030-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabogratinib | Unknown | 60 mg | Oral |
| Subject | Dabogratinib | Unknown | 80 mg | Oral |